CALT News and Press, Calliditas Therapeutics AB From 09/29/23

Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th International Symposium on IgA Nephropathy (IIgANN) Tokyo 2023 PR Newswire STOCKHOLM , Sept. 29, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("...

STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU PR Newswire Request submitted by STADA to EMA to convert conditional marketing authorization to standard marketing authorization for Kinpeygo treatment for primary IgA nephr...

Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib PR Newswire STOCKHOLM , Sept. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") ...

2023-09-21 14:32:43 ET Shares of Calliditas Therapeutics (NASDAQ: CALT) were up more than 14% as of 1 p.m. ET on Thursday. The Swedish pharmaceutical company may have benefited when a competitors' drug announced a mixed trial result. The stock is up 29% this year. Calliditas...

2023-09-21 10:00:13 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Health Care Select Sector SPDR ETF declares quarterly distribution of $0.5395 BofA clients were net buyers of U.S. equities for a fifth...

Calliditas Therapeutics to Present Nefecon Data at the 17th International Symposium on IgA Nephropathy (IIgANN) September 25-27 in Tokyo PR Newswire STOCKHOLM , Sept. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("...

2023-09-03 04:26:46 ET Summary Calliditas Therapeutics downgrades Tarpeyo sales guidance due to slower-than-expected sales growth and market access challenges. Potential growth drivers include full-label expansion of Tarpeyo and addressing the educational gap about the duration of...

Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon® for the Treatment of IgA Nephropathy PR Newswire SHANGHAI , Aug. 20, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or th...

2023-08-18 06:51:30 ET More on Calliditas Calliditas: Riding The Setanaxib Wave And Betting On Tarpeyo's Triumph Calliditas Therapeutics: First Quarter Not As Bad As It Looks Calliditas interim phase 2 data positive for head and neck cancer asset setanaxib Ca...

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy PR Newswire STOCKHOLM , Aug. 18, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT), (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the ...